

18th January, 2017

The Manager, Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

**Re.: Press Release - Panacea Biotec announces ANDA approval for US Market and LTA
& Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT)**

Dear Sir,

The Company is pleased to announce the ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT).

USFDA has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg.

The Company has also entered into Long Term Agreement (LTA) with UNICEF for supply of Pentavalent Vaccine (Easyfive-TT) in calendar year 2017 and also received a Notification from PAHO for purchase of Pentavalent Vaccine (Easyfive-TT) in the event PAHO should have any requirements through 31st December 2019.

A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you,
Sincerely yours,
for **Panacea Biotec Ltd.**



Vinod Goel
Group CFO and Head Legal
& Company Secretary

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com



Panacea Biotec

Innovation in support of life

Press Release

Immediate Distribution

❖ Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT)

New Delhi, Jan 18, 2017:

❖ ANDA approval for US market:

Panacea Biotec today announced that USFDA has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg.

This generic is equivalent to MAXALT-MLT® ODT of Merck & Co. The current Annual sales for Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg in the US market is approximately \$ 60 million.

Rizatriptan Benzoate is a serotonin (5-HT) 1B/1D receptor against (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients.

The Company plans to launch the product within first quarter of 2017 through its distribution partner in US.

Panacea Biotec recently got approval of its anti-cancer formulation facility from USFDA in November, 2016.

❖ LTA & Award from UN Agencies:

Panacea Biotec has entered into Long Term Agreement (LTA) with UNICEF for supply of Pentavalent Vaccine (Easyfive-TT) in calendar year 2017 and also received a Notification from PAHO for purchase of Pentavalent Vaccine (Easyfive-TT) in the event PAHO should have any requirements through 31st December 2019. Total value of this expected business from UN Agencies is worth **USD 20.475 Million** equivalent to around **INR 140 Crore** based on current exchange rate.

Commenting on the developments, **Dr. Rajesh Jain, Joint Managing Director**, Panacea Biotec, said that another product approval by US FDA and UN Agencies business would help the Company to grow in a sustainable manner in mid to long term.

CIN: L33117PB1984PLC022350

Corp Office: B-1 EXT. / A-27, MCIE, Mathura Road, New Delhi 110044, India;

Tel: +91 11 41679000, Ext. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;

Mobile: +91 9312693040; Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com

Skaran



About Panacea Biotec Ltd.

Panacea Biotec is one of India's leading research based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec got recently approval of its anti-cancer formulation facility approval from USFDA. Panacea Biotec is one of the largest vaccine producers in India and is one of the leading Biotechnology Companies. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b) (2) products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems. Panacea Biotec has introduced its products in over 20 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations. The company's state-of-the-art manufacturing facilities for oncology, vaccines and pharmaceutical formulations comply with the US-FDA, European and WHO cGMP standards. The company has around 2,500 employees including around 120 scientists working across 4 R&D centers of the Company.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

For more information, please contact –



P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Ext. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Ext. 1406, 41578080 (Direct)

Fax + 91 11 41578002; Mobile: + 91 9312693040

Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com



CIN: L33117PB1984PLC022350

Corp Office: B-1 EXT. / A-27, MCIE, Mathura Road, New Delhi 110044, India;

Tel: +91 11 41679000, Ext. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;

Mobile: +91 9312693040; Email: pdkaran@panaceabiotec.com ; Web: www.panaceabiotec.com